2. GPCR/G Protein Stem Cell/Wnt Cytoskeleton Cell Cycle/DNA Damage TGF-beta/Smad
  3. LPL Receptor ROCK TGF-beta/Smad TGF-β Receptor
  4. 1-Oleoyl lysophosphatidic acid sodium

1-Oleoyl lysophosphatidic acid sodium  (Synonyms: 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium)

Cat. No.: HY-107614G
Handling Instructions Technical Support

1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA1 and LPA2, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer.

For research use only. We do not sell to patients.

1-Oleoyl lysophosphatidic acid sodium

1-Oleoyl lysophosphatidic acid sodium Chemical Structure

CAS No. : 325465-93-8

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

1-Oleoyl lysophosphatidic acid sodium Related Antibodies

Top Publications Citing Use of Products

View All LPL Receptor Isoform Specific Products:

View All Isoforms
LPAR1 LPAR2 LPAR3 LPAR5 S1PR1 S1PR2 S1PR3 S1PR4 S1PR5

View All ROCK Isoform Specific Products:

View All Isoforms
ROCK ROCK1 ROCK2

View All TGF-β Receptor Isoform Specific Products:

View All Isoforms
ALK1 ALK2 ALK3 ALK4 ALK5 ALK6 ALK7 TGFβR2 ACVR2A ACVR2B BMP

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA1 and LPA2, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer[1][2][3][4].

In Vitro

1-Oleoyl lysophosphatidic acid sodium competitively inhibits the activity of purified bovine serum lysophospholipase D (lysoPLD) in spectrophotometry and fluorescence analysis assays, with Ki values of 9.6 and 1.2 μM[1].
1-Oleoyl lysophosphatidic acid sodium (GMP) (400 nM-10 μM) induces concentration-dependent transient elevation of [Ca2+]i in primary rat and rabbit osteoclasts. Approximately 400 nM of the reagent elicits responses in 50% of the cells, and this response is mediated by Gi/o-coupled LPA1/3 receptors[3].
1-Oleoyl lysophosphatidic acid sodium (GMP) (5 μM) induces sustained retraction of lamellipodia and disrupts the peripheral actin belt in primary rat osteoclasts via a pathway involving Rho-associated kinases[3].
1-Oleoyl lysophosphatidic acid sodium (0-5 μM; 3-18 h) enhances the survival rate of primary rat osteoclasts, inhibits the apoptosis of primary rat osteoclasts, and induces the nuclear translocation of NFATc1 in primary rabbit osteoclasts via the Gi/o-coupled LPA1 receptor pathway[3].
1-Oleoyl lysophosphatidic acid sodium (5 μM; 5 min) induces mild ERK1/2 phosphorylation via a MEK1/2-dependent pathway in RAW 264.7-derived osteoclast-like cells[3].
1-Oleoyl lysophosphatidic acid sodium (0-10 μM; 0-96 h) induces delayed phosphorylation of Smad2 and Smad3 and subsequent expression of α-smooth muscle actin in human adipose tissue-derived mesenchymal stem cells via LPA receptor-dependent and Smad2/3-dependent signaling pathways[4].
1-Oleoyl lysophosphatidic acid sodium (5 μM; 0-48 hours, 4 days) induces the expression of α-smooth muscle actin in human adipose tissue-derived mesenchymal stem cells by stimulating autocrine TGF-β1 secretion and subsequent Smad2 activation[4].
1-Oleoyl lysophosphatidic acid sodium (0-20 μM; 0-48 h) induces the expression and secretion of stromal cell-derived factor-1 (SDF-1) in human adipose tissue-derived mesenchymal stem cells in a dose- and time-dependent manner via LPA receptor-dependent and TGF-β1-dependent signaling pathways[4].
1-Oleoyl lysophosphatidic acid sodium (5 μM; 4 days) induces the differentiation of human adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells (which express α-smooth muscle actin and calmodulin, but not smooth muscle myosin heavy chain)[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1-Oleoyl lysophosphatidic acid sodium Related Antibodies

ELISA Assay[3]

Cell Line: RAW 264.7-derived osteoclast-like cells
Concentration: 5 μM
Incubation Time: 5 min
Result: Induced a small but significant increase in phospho-ERK1/2 levels.
Had effect blocked by 10 μM U0126.

Western Blot Analysis[4]

Cell Line: human adipose tissue-derived mesenchymal stem cells (hADSCs)
Concentration: 0-10 μM (dose-response); 5 μM (time-course); 5 μM (Ki16425 pre-incubation group); 10 μM (Ki16425)
Incubation Time: 4 days (dose-response); 3-96 hours (time-course); 4 days (Ki16425 pre-incubation group)
Result: Increased α-SMA expression dose-dependently, with maximal increase at 5 μM after 4 days.
Increased α-SMA expression starting 48 hours after 5 μM treatment, with maximal levels at 96 hours.
Completely abolished the 5 μM-induced α-SMA expression when pre-incubated with 10 μM Ki16425.

Western Blot Analysis[4]

Cell Line: human adipose tissue-derived mesenchymal stem cells (hADSCs)
Concentration: 5 μM (time-course); 5 μM (Ki16425 pre-incubation group); 10 μM (Ki16425); 10 μM (SIS3); siRNA transfection (Smad2/3); adenoviral Smad7 expression
Incubation Time: 0-96 hours (time-course); 4 days (inhibitor/siRNA/adenovirus groups)
Result: Induced delayed phosphorylation of Smad2 and Smad3, with maximal levels at 48 hours, sustained through 96 hours.
Completely abolished Smad2/3 phosphorylation when pre-incubated with 10 μM Ki16425.
Completely abrogated 5 μM-induced α-SMA expression and corresponding Smad phosphorylation after siRNA-mediated knockdown of Smad2 or Smad3.
Attenuated 5 μM-induced α-SMA expression and Smad3 phosphorylation (but not Smad2 phosphorylation) when pre-incubated with 10 μM SIS3.
Abrogated 5 μM-induced α-SMA expression and Smad2/3 phosphorylation after adenoviral overexpression of Smad7.

Western Blot Analysis[4]

Cell Line: human adipose tissue-derived mesenchymal stem cells (hADSCs)
Concentration: 5 μM
Incubation Time: 4 days
Result: Increased expression of α-SMA and calponin in hADSCs.
Did not induce expression of smooth muscle myosin heavy chain (SM-MHC).
In Vivo

Central administration of 1-Oleoyl lysophosphatidic acid (sodium) (GMP) (0.4-2 μg/5 μL; i.c.v.; single injection) induces anxiogenic-like and depressive-like behaviors in rats in a dose-dependent manner, with the 2 μg dose producing the strongest behavioral effects and increasing c-Fos expression in the DPAG by 94%[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar rats (9-week-old male, 250-300 g)[2]
Dosage: 0.4 μg/5 μL; 2 μg/5 μL
Administration: i.c.v.; single injection
Result: Reduced time spent in open arms by approximately 89% (2 μg dose, elevated plus-maze novelty condition); showed no significant effect on time spent in open arms (0.4 μg dose, elevated plus-maze novelty condition).
Reduced locomotor activity (crossings) by approximately 40% (2 μg dose, open-field test novelty condition); showed no significant effect on locomotor activity (0.4 μg dose, open-field test novelty condition).
Increased locomotor activity by approximately 180% (2 μg dose, open-field test habituation condition); showed no significant effect on locomotor activity (0.4 μg dose, open-field test habituation condition).
Reduced the percentage of rats that first entered the novel arm to chance levels (both doses, Y maze test); significantly reduced total time spent in the novel arm (0.4 μg dose, Y maze test); showed a near-significant reduction in total time spent in the novel arm (p=0.0558, 2 μg dose, Y maze test).
Increased immobility time by 75% (0.4 μg dose, forced swimming test); increased immobility time by 120% (2 μg dose, forced swimming test).
Increased c-Fos immunoreactivity in the dorsal periaqueductal gray matter (DPAG) by 94% (2 μg dose).
Molecular Weight

458.50

Formula

C21H40NaO7P
CAS No.
SMILES

CCCCCCCC/C=C\CCCCCCCC(OC[C@@H](O)COP(O)(O[Na])=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

1-Oleoyl lysophosphatidic acid sodium Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

1-Oleoyl lysophosphatidic acid sodium (GMP)325465-93-81-Oleoyl-sn-glycero-3-phosphate sodium (GMP) 1-Oleoyl-LPA sodium (GMP)LPL ReceptorROCKTGF-beta/SmadTGF-β ReceptorLysophospholipid ReceptorRho-associated protein kinaseRho-associated kinaseRho-kinaseROKTransforming growth factor betaTransforming growth factor beta receptorsbioactive lipid signaling moleculeanxietydepressionovarian cancerosteoclastsmesenchymal stem cellsWistar ratsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
1-Oleoyl lysophosphatidic acid sodium
Cat. No.:
HY-107614G
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.